STAT+: Day 3 at ASGCT: Vinay Prasad speculation, screening newborns, promising data
\n \t
\n
<\/BR>
\n
\n \t
\n
<\/BR><\/p>\n
NEW ORLEANS \u2014 Greetings from the home stretch of American Society of Gene and Cell Therapy conference, where everyone is still talking about Baby KJ <\/a>and no one wants to talk about Vinay Prasad.<\/p>\n Last year, hundreds of people poured in to see Peter Marks, the FDA\u2019s head of biologics, speak at at ASGCT.\u00a0 The regulator was seen by many advocates, researchers and executives\u00a0as an ally in their efforts to get rare disease treatments approved, sometimes despite limited or contradictory evidence.<\/p>\n Now, of course, Marks has been fired by the Trump administration. And among the biggest questions facing the gene therapy field is what stance Vinay Prasad, the fiery hematologist and oft-pharma critic who replaced him, will take toward such rare disease treatments.<\/p>\n Continue to STAT+ to read the full story\u2026<\/a><\/p>\n<\/div>\nThe Vinay Prasad in the room<\/h2>\n